Surrogate Consent in Research
Surrogate Consent in Research
批准号:
7868027
负责人:
MICHELLE Ng GONG
金额:
$40.3万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-04 至 2012-06-30
关键词:
AcuteAddressAdultAgreementAnalysis of VarianceBenefits and RisksChildClinical ResearchCluster AnalysisConflict of InterestConsentCritical CareCross-Sectional StudiesDecision MakingDementiaDependenceEmergency SituationEnrollmentEnsureEthical IssuesEthicsFactor AnalysisFamily memberFundingFutureGeneticGenetic screening methodHealthHumanImpaired cognitionImpairmentIndividualInformed ConsentInstitutionIntensive Care UnitsLawsLeftMeasuresMedicalMedicineMental disordersMultivariate AnalysisNew YorkPatient ParticipationPatient PreferencesPatientsPoliceProcessPublic HealthRegulationRelative RisksResearchResearch Ethics CommitteesResearch ProposalsResearch SubjectsRiskSurveysVacuumVulnerable PopulationsWeightcommon rulecostexperienceresearch studyresponserisk benefit ratio
中文摘要
描述(由申请人提供):在机构审查委员会(irb)和患者的授权代表或代理人的层面上,决定性受损的成年人在临床研究中受到保护。然而,目前尚不清楚irb和代理人同意的做法如何在研究中保护这些个体,特别是在重症监护环境中,当代理人本身可能被认为是脆弱的,或者在涉及基因检测的研究中,代理人可能有潜在的利益冲突。这项提案的主要目的是从伦理委员会和病人及其代理人的角度,审查对那些病得太严重而不能同意的成年人提供的保护。具体来说,我们的目标是1)确定irb在研究中保护决策障碍成人的做法的可变性;2)评估患者及其代理人对重症监护环境中不同风险/收益比的研究的看法。在SA #1中,将对IRB主席进行横断面调查,以确定IRB根据州、联邦资金的数量和涉及精神疾病或痴呆症患者的研究经验建立的保障措施的数量和类型的变化。聚类分析将用于确定可变性和多变量分析,MANACOVA将用于确定与资金和经验的相关性。在SA #2中,重症监护病房的患者和代理人将接受调查,了解他们对代理人决策的看法,并询问他们是否会将患者纳入有基因检测和没有基因检测的不同风险/收益比的假设研究中。患者及其代理人对患者是否参加这些研究的同意将使用加权和未加权Kappa评分来确定。使用因子分析和重复测量方差分析,患者-代孕者的一致程度将与研究的相对风险和潜在获益以及是否提出基因检测相关。这一建议与健康有重要关系。在研究中对无行为能力成年人的保护直接解决了人类研究中的伦理问题,并且在紧急和重症监护环境的研究中日益重要。这项研究计划与公共卫生有关,因为它适用于几乎所有关于急性或严重医疗状况的研究。这项研究的结果将为当前的辩论提供信息,并指导未来的政策,以确保医学的重要进步不会以牺牲我们中最脆弱的群体为代价。
英文摘要
DESCRIPTION (provided by applicant): Decisionally impaired adults are protected in clinical research at the level of the institutional review boards (IRBs) and the authorized representative or surrogate of the patient. However, it is not clear how IRBs and the practice of surrogate consent protect these individuals in research especially in the critical care setting when surrogates may be considered vulnerable themselves or in studies involving genetic testing where the surrogates may have a potential conflict of interest. The broad objective of this proposal is to examine the protections afforded to adults who are too sick to consent from the perspective of the IRBs and the patients and their surrogates. Specifically we aim to 1) determine the variability in IRBs' practices in protecting decisionally impaired adults in research and 2) to assess the views of patient and their surrogates' towards research with differing risk/benefit ratios in the critical care setting. In SA #1, a cross-sectional survey of IRB chairs will be conducted to determine the variability in the number and types of safeguards established by the IRBs according to state, amount of federal funding and experience with research involving patients with mental illness or dementia. Cluster analyses will be used to determine variability and multivariate analyses and MANACOVA will be used to determine correlation with funding and experience. In SA #2, patients and surrogates in intensive care units will be surveyed about their views of surrogate decision making and asked if they would enroll the patient into hypothetical studies with differing risk/benefit ratios with and without genetic testing. Agreement between patients and their surrogates on whether the patient would participate in these studies will be determined using weighted and unweighted Kappa scores. Using factor analyses and Repeated Measures Analysis of Variance, the extent of patient-surrogate agreement will be correlated with the relative risks and potential benefit of the studies and with whether or not genetic testing was proposed. This proposal has important health relatedness. The protection of incapable adults in research directly addresses the PA: Research on Ethical Issues in Human Studies and is an increasingly important issue in research in the emergency and critical care setting. This research proposal is relevant to public health as it applies to almost any research on acute or serious medical conditions. Results from this study will inform the current debate and guide future polices so as to ensure that important advances in medicine does not come at the cost of compromising the most vulnerable among us.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Reply: Antipsychotic Agents and Delirium.
答复:抗精神病药物和谵妄。
DOI:
10.1164/rccm.201505-1037le
发表时间:
2015
期刊:
American journal of respiratory and critical care medicine
影响因子:
24.7
作者:
[Hsieh,SJean, Soto,GracielaJ, Hope,AlukoA, Ponea,Ana, Gong,MichelleN]
通讯作者:
Gong,MichelleN
DOI:
10.1097/ccm.0b013e31823bc9e7
发表时间:
2012-04
期刊:
Critical care medicine
影响因子:
8.8
作者:
[Leung S, Pokharel R, Gong MN]
通讯作者:
Gong MN
TREAT ECARDS: Translating Evidence into Action: Electronic Clinical Decision Support in ARDS
-
批准号:9763432
-
项目类别:
-
资助金额:$39.79万
-
财政年份:2018
-
负责人:MICHELLE Ng GONG
-
依托单位:
Digital Implementation Intervention Trials in Acute Lung Care (DIGITAL-C) Network Planning
-
批准号:9756472
-
项目类别:
-
资助金额:$41.99万
-
财政年份:2018
-
负责人:MICHELLE Ng GONG
-
依托单位:
Utilizing Innovative Technology To Improve Compliance With Patient Elevation Guidelines – The Impact Of Angulus On Adherence To The Evidence-Based VAP-Prevention Bundle
-
批准号:9139729
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2016
-
负责人:MICHELLE Ng GONG
-
依托单位:
Einstein PETAL: Clinical Center for the PETAL Network
-
批准号:9172481
-
项目类别:
-
资助金额:$0.86万
-
财政年份:2014
-
负责人:MICHELLE Ng GONG
-
依托单位:
Einstein PETAL: Clinical Center for the PETAL Network
-
批准号:8704533
-
项目类别:
-
资助金额:$14.42万
-
财政年份:2014
-
负责人:MICHELLE Ng GONG
-
依托单位:
Einstein PETAL: Clinical Center for the PETAL Network
-
批准号:9062498
-
项目类别:
-
资助金额:$27.55万
-
财政年份:2014
-
负责人:MICHELLE Ng GONG
-
依托单位:
Early Insulin Therapy and Development of ARDS
-
批准号:7491770
-
项目类别:
-
资助金额:$45.4万
-
财政年份:2007
-
负责人:MICHELLE Ng GONG
-
依托单位:
Early Insulin Therapy and Development of ARDS
-
批准号:7866687
-
项目类别:
-
资助金额:$41.72万
-
财政年份:2007
-
负责人:MICHELLE Ng GONG
-
依托单位:
Early Insulin Therapy and Development of ARDS
-
批准号:7313911
-
项目类别:
-
资助金额:$48.92万
-
财政年份:2007
-
负责人:MICHELLE Ng GONG
-
依托单位:
Early Insulin Therapy and Development of ARDS
-
批准号:8057652
-
项目类别:
-
资助金额:$46.43万
-
财政年份:2007
-
负责人:MICHELLE Ng GONG
-
依托单位:
Surrogate Consent in Research
-
批准号:7442282
-
项目类别:
-
资助金额:$41.15万
-
财政年份:2006
-
负责人:MICHELLE Ng GONG
-
依托单位:
Surrogate Consent in Research
-
批准号:7074494
-
项目类别:
-
资助金额:$41.96万
-
财政年份:2006
-
负责人:MICHELLE Ng GONG
-
依托单位:
Surrogate Consent in Research
-
批准号:7997343
-
项目类别:
-
资助金额:$41.15万
-
财政年份:2006
-
负责人:MICHELLE Ng GONG
-
依托单位:
Surrogate Consent in Research
-
批准号:7272029
-
项目类别:
-
资助金额:$41.15万
-
财政年份:2006
-
负责人:MICHELLE Ng GONG
-
依托单位:
Molecular Epidemiology of ARDS and Septic Shock
-
批准号:6537979
-
项目类别:
-
资助金额:$13.0万
-
财政年份:2001
-
负责人:MICHELLE Ng GONG
-
依托单位:
Molecular Epidemiology of ARDS and Septic Shock
-
批准号:6756398
-
项目类别:
-
资助金额:$13.0万
-
财政年份:2001
-
负责人:MICHELLE Ng GONG
-
依托单位:
Molecular Epidemiology of ARDS and Septic Shock
-
批准号:6607545
-
项目类别:
-
资助金额:$13.0万
-
财政年份:2001
-
负责人:MICHELLE Ng GONG
-
依托单位:
Molecular Epidemiology of ARDS and Septic Shock
-
批准号:6322056
-
项目类别:
-
资助金额:$13.0万
-
财政年份:2001
-
负责人:MICHELLE Ng GONG
-
依托单位:
Molecular Epidemiology of ARDS and Septic Shock
-
批准号:6898701
-
项目类别:
-
资助金额:$13.0万
-
财政年份:2001
-
负责人:MICHELLE Ng GONG
-
依托单位:
海外基金